All In Biotech

Investigational drug · Phase 2

MRT-2359

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, NSCLC, SCLC.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "MRT-2359"

First trial start

2022

Oct 12, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MRT-2359", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Prostate Cancer
  • NSCLC
  • SCLC
  • High Grade Neuroendocrine Cancer
  • DLBCL
  • L-MYC and N-MYC Amplified Solid Tumors
  • NSCLC With High or Low L-MYC or N-MYC Expression
  • HR-positive, HER2-negative Breast Cancer
  • Castration-Resistant Prostate Cancer (CRPC)
  • Castration-Resistant Prostate Cancer

Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "MRT-2359" as an intervention, largest first.

All trials
  • Monte Rosa Therapeutics, IncIndustry

    NCT05546268 · 174 participants (planned) · Start Oct 12, 2022 · Primary completion Dec 2026

    Drug: Oral MRT-2359; Oral MRT-2359 and 4 more · For: NSCLC; SCLC; High Grade Neuroendocrine Cancer and 5 more

    Sites: Scottsdale, Arizona; San Diego, California; New Haven, Connecticut · 17 sites in all

  • Monte Rosa Therapeutics, IncIndustry

    NCT07745361 · 25 participants (planned) · Start Aug 18, 2026 · Primary completion Oct 2027

    Drug: Oral MRT-2359; Apalutamide · For: Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer and 1 more

    Sites: Los Angeles, California; Newport Beach, California; Colorado Springs, Colorado · 14 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Prostate Cancer

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials

    Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)

  • 64Cu-SAR-bisPSMAPhase 33 trials

    Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms

  • Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials

    Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

  • MevrometostatPF-06821497Phase 33 trials

    Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.